Camizestrant is a medicine used to treat a type of advanced breast cancer that grows with the help of the hormone estrogen. It is taken as a pill by mouth, along with another cancer pill. It works by blocking and breaking down the part of the cancer cell that estrogen uses to make it grow.
Every report comes from a Lived member, sent anonymously.
Have you tried Etcamah (Camizestrant) for Breast Cancer?
Camizestrant, sold as Etcamah, is a prescription hormone therapy for adults with advanced breast cancer that is hormone receptor (HR)-positive and HER2-negative. HR-positive means the cancer uses estrogen to grow; HER2-negative means it does not depend on a growth protein called HER2. Advanced here means the cancer has spread to other parts of the body or cannot be removed with surgery. Its use is narrow and well defined. Many people with this cancer start treatment with an aromatase inhibitor, such as letrozole or anastrozole, which lowers the body's estrogen, combined with a CDK4/6 inhibitor, a targeted pill (abemaciclib, palbociclib or ribociclib) that slows cancer cell division. Over time, the cancer can develop a change in the ESR1 gene, which carries the instructions for the estrogen receptor. This is the most common way the cancer becomes resistant to that combination. Camizestrant is approved for people in whom a blood test finds an ESR1 mutation during that treatment. The aromatase inhibitor is stopped, camizestrant takes its place, and the CDK4/6 inhibitor continues. The FDA granted accelerated approval in 2026, based on the medicine delaying cancer growth. Continued approval depends on further trial results.
Estrogen drives this kind of breast cancer by attaching to estrogen receptors inside the cancer cells, which switches on growth signals. An aromatase inhibitor works by starving the receptor of estrogen. An ESR1 mutation changes the receptor itself so that it can keep sending growth signals even when little estrogen is around, which is why the aromatase inhibitor stops being enough. Camizestrant works on the receptor directly. It binds to the estrogen receptor, blocks it, and marks it for the cell to break down, and it does this for both the normal and the mutated forms. Drugs that act this way are often called oral SERDs (selective estrogen receptor degraders). Pairing it with a CDK4/6 inhibitor attacks the cancer on two fronts: one shuts down the hormone signal, the other slows the cell cycle.
Camizestrant is a 75 mg tablet taken by mouth once a day, at about the same time each day, with or without food. It is taken alongside the CDK4/6 inhibitor the person was already on, usually at the same dose, and treatment continues as long as it is working and side effects are manageable. Swallow the tablet whole; do not cut, crush or chew it, and do not take a tablet that is broken or cracked. If a dose is missed and fewer than 6 hours have passed, take it; after 6 hours, skip that day's dose and take the next one at the usual time. If you vomit after a dose, do not take another that day. Keep the tablets in their original bottle with the drying packet inside. The care team may pause treatment for side effects, and the dose can change if another medicine affects how the body clears camizestrant. People taking ribociclib who have severe liver disease may also need a different dose. These adjustments are made by the prescriber.
The most common effects of camizestrant with a CDK4/6 inhibitor are lower blood counts (white cells, red cells and platelets), tiredness, and vision changes. Low blood counts are partly from the CDK4/6 inhibitor and are tracked with routine blood tests. Vision changes affected about a third of people in the main trial, most often seeing flashes of light, along with blurred or double vision, light sensitivity or new floaters, and dry eyes. They were usually mild, but report them, because the care team may pause treatment and arrange an eye exam. Camizestrant also slows the heart rate. On average the drop was about 13 beats per minute, largest around the second week. For most people this causes no symptoms, but a slow heart rate and changes in the heart's electrical rhythm can be dangerous. Get medical help right away for dizziness, lightheadedness, fainting, a pounding or racing heartbeat, shortness of breath or chest pain.
Camizestrant carries an FDA boxed warning, the agency's most prominent warning, about heart rhythm. It can lengthen the QT interval, a measure on an electrocardiogram (ECG) of how long the heart takes to recharge between beats. When it is combined with ribociclib, which also lengthens the QT interval and raises camizestrant levels, or with other medicines that do the same, the risk of a dangerous irregular heartbeat and sudden death goes up. For that reason, an ECG is done before starting, weekly for the first two weeks and then as needed, and levels of blood salts (electrolytes) are checked and corrected. Other QT-lengthening medicines, and medicines that slow the heart, such as beta-blockers, should be avoided when possible. Tell the team about any heart condition or a slow resting heart rate. Camizestrant changes how the liver processes many other drugs and makes some of them build up, and some medicines lower camizestrant's own levels. Have a pharmacist check every prescription, over-the-counter product and supplement before starting, and before adding anything new until at least two weeks after the last dose of camizestrant. Liver problems should also be mentioned. Camizestrant can harm a developing baby. A pregnancy test is done before starting in anyone who could become pregnant. Women should use effective non-hormonal birth control during treatment and for 4 weeks after the last dose, and men with partners who could become pregnant should use birth control until 1 week after. The CDK4/6 inhibitor taken alongside can call for a longer period after stopping (for men taking palbociclib, it is 3 months), so follow the longest period that applies and confirm it with the care team. Do not breastfeed during treatment or for 1 week after. It may also affect fertility in both women and men.
Switching to camizestrant happens while the cancer is still under control on scans, guided by blood tests (often called liquid biopsies) that look for ESR1 mutations in tumor DNA circulating in the blood every few months. In the trial that led to approval, people who switched went a median of 16 months before their cancer grew (half went longer and half shorter), compared with about 9 months for those who stayed on the aromatase inhibitor. They also kept their quality of life longer. It has not yet been shown whether switching helps people live longer, and results vary from person to person. The first weeks involve more visits for ECGs and heart-rate checks, especially for anyone whose heart rate is already slow or who takes heart-rate-lowering medicine. After that, routine follow-up includes blood counts, scans and attention to vision. Treatment continues until the cancer grows again or side effects become too difficult, at which point the team discusses the next option.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Etcamah (Camizestrant), what you've noticed, or ask the community a question.